Synosia in-licensing renews UCB's Parkinson's hopes
This article was originally published in Scrip
Executive Summary
UCB has acquired the development and commercialisation rights to the private Swiss firm Synosia Therapeutics' Parkinson's disease treatment candidates SYN-115 and SYN-118, building on plans detailed earlier this year to exit the primary care market in the US and to become a "patient-centric", specialty-focused biopharmaceutical company